FDA
-
-
-
-
-
-
-
Artiva reports positive AlloNK trial data, plans phase 3 study in 2026
-
-
-
-
-
-
-
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNKĀ® in Autoimmune Disease
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Artiva Biotherapeutics (ARTV)
323,590 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

